Login
Certara, Inc. logo

Certara, Inc.

certara.com

What Do They Do?

Sells biosimulation software, scientific data tools and consulting services to biopharmaceutical and biotech companies for drug research, development and regulatory submissions.

How Do They Make Money?

Customers buy software licenses, cloud subscriptions, maintenance and consulting; subscriptions and support are generally billed in advance, while service work is billed periodically or at milestones as it progresses.

FY2025 revenue

Who Are Their Customers?

Drug developers and research organizations, academic and government institutions, and regulators use Certara’s software and services. Its commercial team works directly with customers and may use software distributors in some regions or categories.

Do Revenues Turn Into Profits?

Not on paper. It lost $1.6M in FY2025, but brought in more cash than it spent: $94.6M of free cash flow.

Operating income, FY2025
5% of revenue
▲ Turned profitable vs FY2024 (−$1.7M, 0%)
Net income, FY2025
0% of revenue
▲ +87% (Loss) vs FY2024 (−$12.1M, −3%)
Free cash flow, FY2025
23% of revenue
▲ +20% vs FY2024 ($78.8M, 20%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +4%
vs $90.9M in Q3 FY2025
Net income
▲ +267%
vs $1.5M in Q3 FY2025
  • Aug 4, 2026 Reaffirmed full-year revenue growth guidance Certara expects full-year revenue growth of 0% to 4% on a comparable continuing-operations basis.
  • Jun 17, 2026 CFO gave notice of resignation; interim CFO appointed John Gallagher planned to leave effective July 14; Faiz Mohammed was appointed interim CFO effective July 15.
  • May 11, 2026 Sold regulatory and medical writing business to Veristat The sale closed for $85.0 million cash, with $15.0 million in escrow and up to $35.0 million in contingent consideration.

Growing. Revenue grew 46% in 4 years, from $286.1M in FY2021 to $418.8M in FY2025, about 10% a year.

Artificial intelligence tools The latest report describes generative artificial-intelligence tools for life-sciences organizations and regulatory writers, alongside regulatory software and services; the older report describes regulatory submissions software and regulatory professionals.

Chemical research software The latest report includes Chemaxon tools for chemical search, property prediction and analysis, extending the software offering into chemical research alongside biosimulation across drug discovery and development.

Who Do They Compete With?

Competes with Mathworks, Dassault Systemes, Ansys, Simulations Plus, ICON, Metrum Research, qPharmetra, and Pharmetheus

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support